Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina

Circulation

Volumn 99, Issue 22, 1999, Pages 2908-2913

  Soejima, Hirofumi ^c   Ogawa, Hisao ^b   Yasue, Hirofumi ^c   Kaikita, Koichi ^c   Nishiyama, Koichi ^c   Misumi, Kenji ^c   Takazoe, Keiji ^c   Miyao, Yuji ^c   Yoshimura, Michihiro ^c   Kugiyama, Kiyotaka ^c   Nakamura, Shin ^c   Tsuji, Ichiro ^a   Kumeda, Kousuke ^a  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NONE

Author keywords

Angina; Coagulation; Plaque

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0033535978     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2908     Document Type: Article

References (22)

1. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
2. Annex BH, Denning SM, Chnnon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619-622.
3. Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y, Nakamura S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol. 1997;17:2232-2237.
4. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Tsuji I, Kumeda K, Aoyama N. Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am J Cardiol. 1996;78:336-340.
5. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol. 1998;81:22-26.
6. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 1987;69:645-651.
7. Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol. 1989;72:391-396.
8. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of the hemostatic system activation. Blood. 1987;70:343-350.
9. Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and prothrombin fragment 1+2. J Biol Chem. 1979;254:8751-8761.
10. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein associated inhibitor. Blood. 1991;78:394-400.
11. Nakamura S, Kamikubo Y, Okajima K, Asakura H, Nakamura K. Plasma tissue factor: Its sensitive assay and characterization. Thromb Haemost. 1993;69:744. Abstract.
12. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form of TFPI but not lipoprotein-associated forms in plasma. J Biochem. 1995;118:178-182.
13. Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
14. Caplice NM, Muesuke CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 1998;98:1051-1057.
15. Falciani M, Gori AM, Fedi S, Chiarugi L, Simontti I, Dabizzi RP, Neri Serneri GG. Elevated tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost. 1998;79:495-499.
16. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769-771.
17. Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, Masuda M, Takahasi H, Nomura S, Fukuhara S. Expression of functional tissue factor on small vesicle of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Haemost. 1997; 203:820. Abstract.
18. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinol. 1991;2:713-721.
19. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia: Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol. 1996; 16:802-808.
20. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, Van de Loo J. Prothrombin activation fragment 1+2 and thrombin anti-thrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost. 1993;70:550-553.
21. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055-2062.
22. Merlini PA, Bauer KA, Oltrona L, Arddissio D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.